Linical Co., Ltd.
2183・Standard Market・Services
Business
Linical Co., Ltd. is a contract research organization (CRO) established in 2005, engaged in outsourced pharmaceutical development services. Centered on clinical trial monitoring, the company undertakes data management, statistical analysis, medical writing, pharmacovigilance, and other services. It has established a network of operations in Japan, the US, Europe, Asia (Taiwan, South Korea, China), and Australia, building a system capable of providing end-to-end support for international collaborative clinical trials. Its main clients include domestic and overseas pharmaceutical companies as well as emerging biopharmaceutical companies in the US, Europe, and Asia. The company focuses on disease areas with high development difficulty, such as oncology, central nervous system disorders, and immune diseases, differentiating itself from major global CROs. It also operates a post-marketing drug support business and a drug discovery support business, offering a one-stop service covering the entire pharmaceutical lifecycle management.
Business Model
The company concludes contract agreements with clinical trial sponsors such as pharmaceutical companies, and recognizes revenue in line with work performed over the trial period (typically 1 to 3 years, up to approximately 5 years). The order backlog serves as a leading indicator of future revenue, and the order backlog at the end of FY2026 (ending March 2026) stood at ¥11,673 million. The company has a fixed-cost-oriented cost structure centered on personnel expenses, and profitability is heavily influenced by staff utilization rates. Winning contracts for international multi-regional clinical trials by leveraging its global network of sites is the main driver of revenue growth.
Company Strengths
Since its establishment in 2005, the company has progressively expanded its footprint, adding the US (2008), Europe (2014), Taiwan/South Korea (2013), China (2019), and Australia (2024). It has built a system capable of independently covering international collaborative clinical trials, and its ability to generate bidirectional global synergies—such as attracting US and European biotech companies to Asia and supporting Asian biotech companies' entry into the US market—serves as a key differentiator from competitors.
The company focuses on specific disease areas with high unmet medical needs, such as cancer, central nervous system disorders, and immune diseases, and has accumulated the knowledge, technology, and experience needed to execute and support drug development on an equal footing with major pharmaceutical companies. By providing detailed, proposal-based services to emerging biopharmaceutical companies, it differentiates itself from large global CROs and has a track record of expanding its customer base across the US, Europe, and Asia.
In addition to its CRO business (clinical development), the company operates a post-marketing drug development support business (post-marketing clinical research and surveys) and a drug discovery support business (development strategy formulation, regulatory affairs support, and partnering support). In April 2025, the post-marketing drug development support business was integrated into the CRO business, further strengthening the one-stop service provision system. The ability to comprehensively supplement functions that emerging biopharmaceutical companies do not possess in-house is a strength in customer acquisition.
ENVALITH's Perspective
Performance Trend
Revenue peaked at ¥12,517 million in FY2023 (ended March 2023) and has declined for three consecutive fiscal years, reaching ¥8,665 million in FY2026 (ending March 2026), down 17.0% year on year. By region, the United States saw a sharp decline from ¥3,708 million to ¥1,993 million, and Europe from ¥2,644 million to ¥2,195 million. An external factor directly impacting results was delays in trial initiation caused by the U.S. government shutdown and related events. On the other hand, Japan (¥3,254 million to ¥3,455 million) and Asia (¥831 million to ¥1,022 million) saw revenue growth. Operating loss widened to ¥2,073 million (from ¥583 million in the prior period), and with an impairment loss of ¥989 million and a deferred tax asset write-down of ¥297 million added, net loss reached ¥3,329 million. The order backlog stood at ¥11,298 million as of May 15, 2026, down only 3.7% from the end of FY2025 (ended March 2025), and this warrants close monitoring as a leading indicator of revenue recovery.
Growth Strategy
Rebuilding the profit base through the resumption of delayed U.S. and European projects and the expansion of new orders in Asia
For several large-scale international joint clinical trials whose start had been delayed due to factors including U.S. government shutdowns, some have already resumed operation, and the remaining projects are expected to become operational in stages. Substantial improvement in both revenue and profit is expected in the second half.
The company is in negotiations for several large-scale projects, mainly in the U.S., and expects performance improvement in the second half premised on order acquisition and steady progress. It has received numerous inquiries, including global projects centered on biotech companies, and is focusing on building up its order backlog.
The company is advancing support for Taiwanese biotech companies entering the U.S. market, securing data management and statistical analysis work orders in South Korea, and increasing inquiries through the strengthening of its local sales structure in China. The Asia order backlog was the only region to increase, up 25.4% from the end of FY2025 (ended March 2025).
Leveraging its Australian subsidiary (Linical Australia PTY Ltd), the company has secured orders for Australia/Asia trials project-managed by Japanese pharmaceutical companies. It is also responding to the development needs of Asian biotech companies aiming for the U.S. market via Australia.
At the end of the previous fiscal year, the company reduced fixed costs by streamlining personnel in regions where no prospect of utilization rate improvement was foreseen. It continues to aim for performance improvement through measures to raise personnel utilization rates and strict expense management.
Last updated: July 19, 2026